



SolAeroMed Inc
Research Transition Facility
3535 Research Rd NW
Calgary T2L 2K8

email: info@solaeromed.com
www.solaeromed.com

Newsletter #3 December 18, 2012

Dear SolAeroMed shareholders,

On behalf of our SolAeroMed team, I hope this update finds you healthy & interested in learning how your investment in our company is developing. We endeavor to keep you informed of developments through our revised web site at www.solaeromed.com and through these periodic newsletters.

SolAeroMed held its 1st Annual General Meeting June 27th 2012 and presented to shareholders its new management board, summarized work to date and outlined future plans. Since then, during the 2nd half of 2012 we have made steady progress at SolAeroMed and we can generally report that plans to develop S-1226 remain on track.

We received encouraging advice from Health Canada at a pre-Clinical Trial Application meeting in Ottawa June 4. We have since completed additional pre-clinical experiments and prepared the S-1226 Clinical Trial Application dossier.

We continue to successfully pursue research grant funding to support our development:

- SolAeroMed has benefited greatly from National Research Council (IRAP program) funding and we are pleased to report funding will continue and expand totaling \$250,000 through 2013.
- Prof Francis Green (SolAeroMed CSO) won a competitive grant to support S-1226 development for \$200,000.
- Prof Matthias Amrein recently acquired over \$700,000 in competitive research funding for pre-clinical development of S-1229.

In early 2013 SolAeroMed will submit the S-1226 CTA. This will be a milestone event in our business development plan. If our CTA is accepted by Health Canada regulators, we will be in position to initiate first in human clinical trials of our drug in a Phase I (safety & efficacy) Clinical Trial. All going well, we anticipate S-1226 will require some \$5 million to progress development through Phases I, IIa and IIb human clinical trials. We continue to actively explore funding options for our clinical development program. We endeavor to keep SolAeroMed shareholders informed of developments through www.solaeromed.com and via periodic newsletters.

On behalf of the SolAeroMed team, I wish you health and happiness in 2013.

Dr John Dennis
CEO